DESTINY-Breast05 is a large phase 3 trial in women with HER2-positive early-stage breast cancer who had chemotherapy and ...

AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) said their jointly developed breast cancer therapy ENHERTU has ...

Landscape of Concomitant Driver Alterations in Classical EGFR-Mutated Non–Small Cell Lung Cancer RNA sequencing was performed on 647 previously untreated stage I-III estrogen receptor–positive/human ...

In the AXSANA/EUBREAST 3(R) study, researchers compared data about recurrence outcomes of more-invasive and less-invasive lymph node procedures.

A weak correlation was found between RS and both patient age and tumor size, modest correlation between RS and tumor grade, and modest correlation between RS and 10-year recurrence as determined by ...

A new statistical tool that combines multiple clinical and pathologic factors with a patient's 21-gene Oncotype DX Breast Recurrence Score ® result provides more accurate estimates about that ...

Studying a person's genetic makeup can predict if they will go on to develop invasive breast cancer after abnormal cells have been found in their breast tissue. For the first time, researchers at King ...

—For certain older patients with low-genomic-risk, early-stage breast cancer, the findings from a new study suggest that some of them may be able to forgo either radiotherapy or endocrine therapy ...